Brief: Cutia Therapeutics Says Q4 Revenue Of Group's Commercialized Products RMB72.8 Million
29/02/2024 01:02
Feb 29 (Reuters) - Cutia Therapeutics 2487.HK :
* IN Q4 REVENUE OF GROUP'S COMMERCIALIZED PRODUCTS AMOUNTED
TO
ABOUT RMB72.8 MILLION
Source text for Eikon: ID:nHKSc0XYck
Further company coverage: 2487.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cutia Therapeutics
See all newsBrief: Cutia Therapeutics To Implement Share Repurchase Program From Oct 2 To Dec 31
Brief: Cutia Therapeutics Says Cu-40102 Bags Marketing Approval From Macao Pharmaceutical Administration Bureau
Brief: Cutia Therapeutics Says Nmpa Accepts Biologics License Application For Cu-20101
Brief: Cutia Therapeutics Posts HY Loss Of RMB180.4 MLN
Brief: Cutia Therapeutics Says CU-30101 Obtains Drug Marketing Authorization By NMPA China